Article -> Article Details
| Title | Cell and Gene Therapy Market Technologies, Demand, Growth, Research And Development 2027 |
|---|---|
| Category | Business --> Business Services |
| Meta Keywords | Cell and Gene Therapy Market, Cell and Gene Therapy Market report, Cell and Gene Therapy industry, Cell and Gene Therapy Market size, Cell and Gene Therapy Market value |
| Owner | bis swati |
| Description | |
| Cell and gene therapy are overlapping fields of biomedical research having similar therapeutic goals, which target DNA or RNA inside or outside the body. Both therapies aim at modifying genetic material for treatment of a disease. Gene therapy uses genetic material, or DNA, to manipulate a patient’s cells for the treatment of an inherited or acquired disease. Cell therapy is the introduction of new cells into a patient’s body to grow, replace or repair damaged tissue to treat a disease. The cell and gene therapies are categorized into several therapeutic class, such as rare diseases, oncology, hematology, cardiovascular, ophthalmology, neurology, and others. The global cell and gene therapy market was valued at $2,599.7 million in 2020, and it is expected to grow at an impressive double-digit rate of 33.82% and reach a value of $25,002.1 million in 2027. The existing cell and gene therapy market is favored by multiple factors, which include increasing incidences of cancer and other chronic diseases, rising number of clinical trials, increasing funding and investments in the cell and gene therapy market, and favorable regulatory environment and FDA Approvals for cell and gene therapy products. View the Report on BIS Research - Global Cell and Gene Therapy Market Competitive Landscape The global cell and gene therapy market witnessed 14 mergers and acquisitions, 14 product launches and approvals, 13 joint ventures, and nine business expansions. 14 mergers and acquisitions, 14 product launches and approvals, 13 joint ventures, and nine business expansions. Major players within the cell and gene therapy market are Amgen Inc., bluebird bio, Inc., Castle Creek Pharmaceutical Holdings., Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Spark Therapeutics, Inc., Vericel Corporation, Dendreon Pharmaceuticals LLC., Human Stem Cells Institute, Kolon TissueGene, Inc., Organogenesis Holdings Inc., Pfizer, Inc., RENOVA THERAPEUTICS, Shanghai Sunway Biotech Co. Ltd., and Sibiono GeneTech Co. Ltd. Market Segmentation • By Product Type: Yescarta, Provenge, Luxtura, Kymriah, Imlygic, Gintuit, MACI, Laviv, Gendicine, Oncorine, Neovasculgen, Strimvelis, Invossa, Zolgenesma, Tecartus, Liso-Cel, Zyntelego, Others • By Therapeutic Class: Rare Diseases, Oncology, Hematology, Cardiovascular, Ophthalmology, Neurology and Other Therapeutic Classes • By Region: North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World Regional Segmentation • North America – Country Specific Stratification • Europe – Country Specific Stratification • Asia-Pacific – Country Specific Stratification • Latin America – Country Specific Stratification • Rest-of-the-World Growth Drivers • Increasing Incidences of Cancer and other Chronic Diseases • Rising Number of Clinical Trials • Increasing Funding and Investments in Cell and Gene Therapy Market • Favorable Regulatory Environment and FDA Approvals for Cell and Gene Therapy Products Market Challenges • Lack of Reliable Vector Production for Cell and Gene Therapy • Complex Manufacturing and Distribution Setup • Tedious Process of Therapeutic Commercialization Market Opportunities • Drug Approvals and Strong Pipeline of Cell and Gene Therapies • Increasing Number of Mergers and Acquisitions within the Cell and Gene Industry Key Cell and Gene Therapy Companies Profiled Amgen Inc., bluebird bio, Inc., Castle Creek Pharmaceutical Holdings., Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Spark Therapeutics, Inc., Vericel Corporation, Dendreon Pharmaceuticals LLC., Human Stem Cells Institute, Kolon TissueGene, Inc., Organogenesis Holdings Inc., Pfizer, Inc., RENOVA THERAPEUTICS, Shanghai Sunway Biotech Co. Ltd., and Sibiono GeneTech Co. Ltd. Key Questions Answered in this Report:• What are the different types of approved cell and gene therapies available in the respective market? Get Free Sample Report - https://bisresearch.com/requestsample?id=1062type=download Within the research report, the market is segmented on the basis of product type (Yescarta, Provenge, Luxtura, Kymriah, Imlygic, Gintuit, MACI, Laviv, Gendicine, Oncorine, Neovasculgen, Strimvelis, Invossa, Zolgenesma, Tecartus, Liso-cel, Zyntelego, Others), therapeutic class type (Yescarta, Provenge, Luxtura, Kymriah, Imlygic, Gintuit, MACI, Laviv, Gendicine, Oncorine, Neovasculgen, Strimvelis, Invossa, Zolgenesma, Tecartus, Liso-cel, Zyntelego, Others), and region (North America, Europe, Asia Pacific, Latin America, and Rest-of-the-World). This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, and future opportunities, among other analyses, to detail the scope and provide a 360-coverage of the domain. BIS Research Related Market Studies: Global CRISPR Gene Editing Market - Analysis and Forecast, 2020-2030 | |